Supernus Pharmaceuticals SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 2, 2026, 10:50 a.m. ETView on SEC.gov
Delisting notice / failure to meet listing standard
AI summary, unreviewedSupernus Pharmaceuticals, Inc. Stock to Be Delisted From Nasdaq Following Completion of Merger on November 2, 2026
8-KNov. 2, 2026, 9:28 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Completion of acquisition or disposition of assets · Creation of a direct financial obligation · Material modification of security holders' rights · Change in control · Amendments to articles or bylaws; fiscal year change · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedSupernus completes reverse merger with Indivior, issuing 1.5401 Indivior shares per Supernus share and funding a $1.0 billion Indivior special dividend with a $650 million Citibank term loan
8-KOct. 29, 2026, 4:08 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedSupernus Q3 2026 Revenue Rises 18% to Record $226.8 Million, Beats $217.6 Million Consensus; Diluted EPS of $0.35 Misses $0.49 Estimate; FY2026 Guidance Raised, Indivior Merger Closing November 2
8-KOct. 26, 2026, 4:41 p.m. ETView on SEC.gov
Termination of a material definitive agreement · Financial statements and exhibits
AI summary, unreviewedSupernus Pharmaceuticals Terminates Uncommitted $ UBS Credit Line Ahead of Indivior Combination
8-KOct. 21, 2026, 9:07 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
AI summary, unreviewedSupernus Pharmaceuticals Recognized for Seven-Year ONAPGO Orphan-Drug Exclusivity; Second-Supplier sNDA Submitted, Approval Expected Mid-2027
8-KOct. 19, 2026, 4:51 p.m. ETView on SEC.gov
Results of operations and financial condition
AI summary, unreviewedSupernus Pharmaceuticals (SUPN) to report Q3 2026 results after market close on October 29, 2026
8-KOct. 15, 2026, 4:10 p.m. ETView on SEC.gov
Submission of matters to a vote of security holders · Financial statements and exhibits
8-KAug. 3, 2026, 6:46 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
8-KAug. 3, 2026, 5 p.m. ETView on SEC.gov
Other events · Financial statements and exhibits
8-KAug. 3, 2026, 8:34 a.m. ETView on SEC.gov
Other events · Financial statements and exhibits
8-KAug. 3, 2026, 6:43 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Departure/appointment of directors or officers · Other events · Financial statements and exhibits